$AERT
Aeries Technology, Inc.

2022 Q4 Form 10-K Financial Statement

#000119312523088368 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $0.00 $202.5K
YoY Change
Cost Of Revenue $10.37M
YoY Change
Gross Profit $2.318M
YoY Change
Gross Profit Margin
Selling, General & Admin $2.025M
YoY Change
% of Gross Profit 87.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.362M $4.464M
YoY Change 299.55% 616.89%
Operating Profit $293.0K -$4.464M
YoY Change -206.48%
Interest Expense $2.496M $14.02M
YoY Change -227.47% -816.11%
% of Operating Profit 851.82%
Other Income/Expense, Net $0.00 $202.5K
YoY Change -100.0% -151.06%
Pretax Income $133.6K $9.760M
YoY Change -104.54% -427.82%
Income Tax $742.0K
% Of Pretax Income 555.22%
Net Earnings $133.6K $9.760M
YoY Change -104.54% -427.82%
Net Earnings / Revenue 4820.61%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.34
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.13K $48.13K
YoY Change -90.44% -90.44%
Cash & Equivalents $48.13K
Short-Term Investments
Other Short-Term Assets $8.334K $312.6K
YoY Change -97.92% -21.85%
Inventory
Prepaid Expenses $304.3K
Receivables
Other Receivables
Total Short-Term Assets $360.8K $360.8K
YoY Change -60.06% -60.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $234.7M $234.7M
YoY Change 1.03% 1.03%
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $234.7M $234.7M
YoY Change 0.9% 0.9%
TOTAL ASSETS
Total Short-Term Assets $360.8K $360.8K
Total Long-Term Assets $234.7M $234.7M
Total Assets $235.1M $235.1M
YoY Change 0.66% 0.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $676.7K $676.7K
YoY Change 23980.14% 23980.07%
Accrued Expenses $42.27K $3.133M
YoY Change -76.56% 498.28%
Deferred Revenue
YoY Change
Short-Term Debt $200.0K $200.0K
YoY Change -4.06% -4.06%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.010M $4.010M
YoY Change 924.09% 445.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $957.5K $957.5K
YoY Change -95.36% -95.36%
Total Long-Term Liabilities $957.5K $957.5K
YoY Change -95.36% -95.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.010M $4.010M
Total Long-Term Liabilities $957.5K $957.5K
Total Liabilities $4.968M $4.968M
YoY Change -76.37% -76.75%
SHAREHOLDERS EQUITY
Retained Earnings -$4.507M
YoY Change -77.23%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.507M $230.1M
YoY Change
Total Liabilities & Shareholders Equity $235.1M $235.1M
YoY Change 0.66% 0.66%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $133.6K $9.760M
YoY Change -104.54% -427.82%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$36.89K -$446.6K
YoY Change -95.61% -46.8%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.460K -8.461K
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -36.89K -446.6K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -8.460K -8.461K
Net Change In Cash -45.35K -455.1K
YoY Change -109.02% -190.44%
FREE CASH FLOW
Cash From Operating Activities -$36.89K -$446.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001853044
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40920
CY2022 dei Entity Registrant Name
EntityRegistrantName
Worldwide Webb Acquisition Corp.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1587626
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
770 E Technology Way F13-16
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Orem
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84097
CY2022 dei City Area Code
CityAreaCode
415
CY2022 dei Local Phone Number
LocalPhoneNumber
629-9066
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
226320000
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2021Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Net Derivative Asset Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
Los Angeles, CA
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022Q4 us-gaap Cash
Cash
48126
CY2021Q4 us-gaap Cash
Cash
503204
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
304314
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
400073
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8334
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0
CY2022Q4 us-gaap Assets Current
AssetsCurrent
360774
CY2021Q4 us-gaap Assets Current
AssetsCurrent
903277
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
234716046
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
232320844
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
302847
CY2022Q4 us-gaap Assets
Assets
235076820
CY2021Q4 us-gaap Assets
Assets
233526968
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
676652
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2810
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
200000
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
208461
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3091220
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
168810
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42267
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11501
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4010139
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
391582
CY2022Q4 wwacu Deferred Underwriting Fees Payable Non Current
DeferredUnderwritingFeesPayableNonCurrent
0
CY2021Q4 wwacu Deferred Underwriting Fees Payable Non Current
DeferredUnderwritingFeesPayableNonCurrent
8050000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
614040
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
12240000
CY2022Q4 wwacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
343437
CY2021Q4 wwacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
343437
CY2022Q4 us-gaap Liabilities
Liabilities
4967616
CY2021Q4 us-gaap Liabilities
Liabilities
21025019
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.2
CY2021Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.1
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4507417
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19798626
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4506842
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-19798051
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235076820
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233526968
CY2022 wwacu Formation Costs
FormationCosts
4463907
wwacu Formation Costs
FormationCosts
279246
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-4463907
us-gaap Operating Income Loss
OperatingIncomeLoss
-279246
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11625960
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1978800
CY2022 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
2395202
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
20844
CY2022 wwacu Transaction Costs Allocation To Derivative Warrant Liabilities
TransactionCostsAllocationToDerivativeWarrantLiabilities
0
wwacu Transaction Costs Allocation To Derivative Warrant Liabilities
TransactionCostsAllocationToDerivativeWarrantLiabilities
396497
CY2022 us-gaap Underwriting Income Loss
UnderwritingIncomeLoss
202458
us-gaap Underwriting Income Loss
UnderwritingIncomeLoss
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9759713
us-gaap Net Income Loss
NetIncomeLoss
-2633699
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-19798051
CY2022 wwacu Increase Decrease On Settlement Of Underwriting Fees
IncreaseDecreaseOnSettlementOfUnderwritingFees
7847542
CY2022 wwacu Accretion Of Classa Ordinary Shares To Redemption Value
AccretionOfClassaOrdinarySharesToRedemptionValue
2316046
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9759713
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4506842
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
8306250
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4423300
wwacu Accretion Of Classa Ordinary Shares To Redemption Value
AccretionOfClassaOrdinarySharesToRedemptionValue
29918902
us-gaap Net Income Loss
NetIncomeLoss
-2633699
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-19798051
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9759713
us-gaap Net Income Loss
NetIncomeLoss
-2633699
CY2022 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
2395202
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
20844
CY2022 wwacu Transaction Costs Allocated To Derivative Warrant Liability
TransactionCostsAllocatedToDerivativeWarrantLiability
0
wwacu Transaction Costs Allocated To Derivative Warrant Liability
TransactionCostsAllocatedToDerivativeWarrantLiability
396497
CY2022 wwacu Formation Costs Funded By Note Payable Through Sponsor
FormationCostsFundedByNotePayableThroughSponsor
0
wwacu Formation Costs Funded By Note Payable Through Sponsor
FormationCostsFundedByNotePayableThroughSponsor
22347
CY2022 us-gaap Underwriting Income Loss
UnderwritingIncomeLoss
202458
us-gaap Underwriting Income Loss
UnderwritingIncomeLoss
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11625960
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1978800
CY2022 wwacu Formation And Operating Expenses Paid In Exchange For Founder Shares
FormationAndOperatingExpensesPaidInExchangeForFounderShares
0
wwacu Formation And Operating Expenses Paid In Exchange For Founder Shares
FormationAndOperatingExpensesPaidInExchangeForFounderShares
20421
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-390272
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
702920
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
673842
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2810
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2953176
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
97074
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-446617
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-839514
CY2022 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
232300000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232300000
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
65000
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
8461
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
5000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
230000000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8900000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5317282
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8461
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
233642718
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-455078
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
503204
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
503204
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48126
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
503204
CY2022 wwacu Initial Classa Shares Subject To Possible Redemption
InitialClassaSharesSubjectToPossibleRedemption
0
wwacu Initial Classa Shares Subject To Possible Redemption
InitialClassaSharesSubjectToPossibleRedemption
202381098
CY2022 wwacu Accretion Of Classa Ordinary Shares To Redemption Value
AccretionOfClassaOrdinarySharesToRedemptionValue
2316046
wwacu Accretion Of Classa Ordinary Shares To Redemption Value
AccretionOfClassaOrdinarySharesToRedemptionValue
29918902
CY2022 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
83237
CY2022 wwacu Deferred Offering Costs Paid Through Promissory Note Related Party
DeferredOfferingCostsPaidThroughPromissoryNoteRelatedParty
0
wwacu Deferred Offering Costs Paid Through Promissory Note Related Party
DeferredOfferingCostsPaidThroughPromissoryNoteRelatedParty
126114
CY2022 wwacu Offering Costs Paid Through Prepaid Legal Expense Funded By Sponsor
OfferingCostsPaidThroughPrepaidLegalExpenseFundedBySponsor
0
wwacu Offering Costs Paid Through Prepaid Legal Expense Funded By Sponsor
OfferingCostsPaidThroughPrepaidLegalExpenseFundedBySponsor
4579
CY2022 wwacu Offering Costs On Founder Shares Offered To Anchor Investors
OfferingCostsOnFounderSharesOfferedToAnchorInvestors
0
wwacu Offering Costs On Founder Shares Offered To Anchor Investors
OfferingCostsOnFounderSharesOfferedToAnchorInvestors
8306250
CY2022 wwacu Supplemental Disclosure Of Non Cash Activities Of Deferred Legal Fees
SupplementalDisclosureOfNonCashActivitiesOfDeferredLegalFees
0
wwacu Supplemental Disclosure Of Non Cash Activities Of Deferred Legal Fees
SupplementalDisclosureOfNonCashActivitiesOfDeferredLegalFees
343437
CY2022 wwacu Supplemental Disclosure Of Non Cash Activities Of Deferred Underwriting Fees Payable
SupplementalDisclosureOfNonCashActivitiesOfDeferredUnderwritingFeesPayable
0
wwacu Supplemental Disclosure Of Non Cash Activities Of Deferred Underwriting Fees Payable
SupplementalDisclosureOfNonCashActivitiesOfDeferredUnderwritingFeesPayable
8050000
CY2022 wwacu Initial Derivate Warrant Liability
InitialDerivateWarrantLiability
0
wwacu Initial Derivate Warrant Liability
InitialDerivateWarrantLiability
10261200
CY2022 wwacu Adjustment To Retained Earnings Gain On Settlement Of Underwriting Fees
AdjustmentToRetainedEarningsGainOnSettlementOfUnderwritingFees
-7847542
wwacu Adjustment To Retained Earnings Gain On Settlement Of Underwriting Fees
AdjustmentToRetainedEarningsGainOnSettlementOfUnderwritingFees
0
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2021-03-05
CY2021Q4 wwacu Offering Costs
OfferingCosts
21834402
CY2021Q4 wwacu Deferred Underwriting Fees Payable Non Current
DeferredUnderwritingFeesPayableNonCurrent
8050000
CY2021Q4 wwacu Underwriting Fees
UnderwritingFees
4600000
CY2021Q4 wwacu Other Offering Costs
OtherOfferingCosts
9184402
CY2021Q4 wwacu Offering Costs On Founder Shares Offered To Anchor Investors
OfferingCostsOnFounderSharesOfferedToAnchorInvestors
8306250
CY2021Q4 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
232300000
CY2021Q4 wwacu Deferred Underwriting Fees Payable Non Current
DeferredUnderwritingFeesPayableNonCurrent
8050000
CY2022 wwacu Period Within Which Business Combination Shall Be Consummated From The Closing Of Initia Public Offer
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheClosingOfInitiaPublicOffer
P18M
CY2022Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2022Q4 us-gaap Cash
Cash
48126
CY2022Q4 wwacu Net Working Capital
NetWorkingCapital
3649365
CY2022 wwacu Percentage Of Fair Market Value Of Shares Repurchased
PercentageOfFairMarketValueOfSharesRepurchased
0.01
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230000000
CY2021 wwacu Common Stock Class A Share Issuance Costs
CommonStockClassAShareIssuanceCosts
-21834402
CY2021 wwacu Fair Value Of Public Warrants At Issuance
FairValueOfPublicWarrantsAtIssuance
-5784500
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2022Q4 us-gaap Cash
Cash
48126
CY2021Q4 us-gaap Cash
Cash
503204
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022 us-gaap Derivatives Methods Of Accounting Nonhedging Derivatives
DerivativesMethodsOfAccountingNonhedgingDerivatives
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for the Warrants, Forward Purchase Agreement (as defined below), and Working Capital Loan conversion option (collectively, the “Instruments”) in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> under which the Instruments do not meet the criteria for equity treatment and must be recorded as liabilities. The conversion feature within the Working Capital Loan gives the Sponsor an option to convert the loan to warrants </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the Company’s Class A ordinary shares. This bifurcated feature is assessed at the end of each reporting period to conclude whether additional liability should be recorded. The Instruments are subjected to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. See Note 5 and 7 for further discussion of the pertinent terms of the Warrants and Forward Purchase Agreement and Note 8 for further discussion of the methodology used to determine the value of the Warrants, Forward Purchase Agreement, and Working Capital Loan conversion option. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>changes in the fair value reported in the statements of operations. The classification of derivative<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or noncurrent based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>within 12 months of the balance sheet date. </div>
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
234716046
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
232320844
CY2021 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
29918902
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
232300000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2316046
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
234616046
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. At December 31, 2022 and 2021, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
180361
CY2022 wwacu Deferred Underwriting Fee Percent On Gross Proceeds Of The Ipo
DeferredUnderwritingFeePercentOnGrossProceedsOfTheIpo
3.5
CY2022Q4 wwacu Deferred Underwriting Discount
DeferredUnderwritingDiscount
8050000
CY2022 wwacu Overallotmentoptionvestingperiod
Overallotmentoptionvestingperiod
P45D
CY2022 wwacu Deferred Underwriting Fees Waived
DeferredUnderwritingFeesWaived
8050000
CY2022 wwacu Gain On Settlement Of Underwriting Fees
GainOnSettlementOfUnderwritingFees
202548
CY2021Q3 wwacu Class Of Warrant Or Right Issued During Period Warrants
ClassOfWarrantOrRightIssuedDuringPeriodWarrants
20400000
CY2021Q3 wwacu Class Of Warrant Or Right Redemption Threshold Consecutive Trading Days
ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays
P30D
CY2021Q3 wwacu Class Of Warrant Or Right Threshold Period For Exercise From Date Of Closing Public Offering
ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering
P12M
CY2022 wwacu Class Of Warrant Or Right Redemption Threshold Consecutive Trading Days
ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays
P30D
CY2022 wwacu Class Of Warrant Or Right Threshold Period For Exercise From Date Of Closing Public Offering
ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering
P12M
CY2022 wwacu Number Of Business Day After The Closing Of The Initial Business Combination For Registration
NumberOfBusinessDayAfterTheClosingOfTheInitialBusinessCombinationForRegistration
P15D
CY2022Q4 wwacu Class Of Warrants Redemption Price Per Unit
ClassOfWarrantsRedemptionPricePerUnit
0.1
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 wwacu Percentage Of Common Stock Outstanding
PercentageOfCommonStockOutstanding
0.20
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
614040
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
12240000
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
CY2021Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
9054000
CY2021Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
3186000
CY2021Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
12240000
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
-11625960
CY2022Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
614040

Files In Submission

Name View Source Status
0001193125-23-088368-index-headers.html Edgar Link pending
0001193125-23-088368-index.html Edgar Link pending
0001193125-23-088368.txt Edgar Link pending
0001193125-23-088368-xbrl.zip Edgar Link pending
d749264d10k.htm Edgar Link pending
d749264dex311.htm Edgar Link pending
d749264dex321.htm Edgar Link pending
d749264dex45.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d749264d10k_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wwacu-20221231.xsd Edgar Link pending
wwacu-20221231_def.xml Edgar Link unprocessable
wwacu-20221231_lab.xml Edgar Link unprocessable
wwacu-20221231_pre.xml Edgar Link unprocessable
wwacu-20221231_cal.xml Edgar Link unprocessable